New data suggests that retatrutide, a dual-action medication, might represent a considerable improvement in weight reduction . This drug combines the properties of a GLP-1 receptor and a GIP analog, potentially offering a greater impact than available therapies . Clinical research have revealed promising results , including substantial reductions